Letter to the Editor| Volume 404, P44-46, September 15, 2019

Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease


      • Continuous apomorphine infusion represents an established treatment for advanced Parkinson's Disease (PD).
      • Acute lethargy was repeatedly observed following abrupt apomorphine withdrawal.
      • Profound lethargy was not associated to severe akinetic state and was solved only after restoring apomorphine.
      • Lethargy might be a symptom of acute apomorphine withdrawal.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Trenkwalder C.
        • Chaudhuri K.R.
        • García Ruiz P.J.
        • et al.
        Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease—clinical practice recommendations.
        Parkinsonism Relat. Disord. 2015; 21: 1023-1030
        • Onofrj M.
        • Thomas A.
        Acute akinesia in Parkinson disease.
        Neurology. 2005; 64: 1162-1169
        • Rabinak C.A.
        • Nirenberg M.J.
        Dopamine agonist withdrawal syndrome in Parkinson disease.
        Arch. Neurol. 2010; 67: 58-63
        • Limotai N.
        • Oyama G.
        • Go C.
        • et al.
        Addiction-like manifestations and Parkinson’s disease: a large single center 9-year experience.
        Int. J. Neurosci. 2012; 122: 145-153
        • Sacks O.
        Duckworth, London1973
        • Sierra M.
        • Carnicella S.
        • Strafella A.P.
        • et al.
        Apathy and impulse control disorders: yin & Yang of dopamine dependent Behaviors.
        J. Park. Dis. 2015; 5: 625-636
        • Sacks O.W.
        • Messeloff C.R.
        • Schwartz W.F.
        Long-term effects of levodopa in the severely disabled patient.
        JAMA. 1970; 213: 2270
        • Frucht S.
        • Rogers J.D.
        • Greene P.E.
        • Gordon M.F.
        • Fahn S.
        Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.
        Neurology. 1999; 52: 1908-1910
        • Raggi A.
        • Bella R.
        • Pennisi G.
        • Neri W.
        • Ferri R.
        Sleep disorders in Parkinson’s disease: a narrative review of the literature.
        Rev. Neurosci. 2013; 24: 279-291
        • Delpont B.
        • Lhommée E.
        • Klinger H.
        • et al.
        Psychostimulant effect of dopaminergic treatment and addictions in Parkinson’s disease.
        Mov. Disord. 2017; 32: 1566-1573
        • Kramer J.C.
        • Fischman V.S.
        • Littlefield D.C.
        Amphetamine abuse. Pattern and effects of high doses taken intravenously.
        JAMA. 1967; 201: 305-309
        • Shoptaw S.J.
        • Kao U.
        • Heinzerling K.
        • et al.
        Treatment for amphetamine withdrawal. Cochrane Database Of Systematic Reviews.
        2009 (Issue 2. Art. No.:CD003021)
        • Gosseries O.
        • Charland-Verville V.
        • Thonnard M.
        • et al.
        Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness.
        Curr. Pharm. Des. 2014; 20: 4167-4184
        • Schiff N.D.
        Recovery of consciousness after brain injury: a mesocircuit hypothesis.
        Trends Neurosci. 2010; 33: 1-9
        • Jenner P.
        • Katzenschlager R.
        Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease.
        Parkinsonism Relat. Disord. 2016; 33: S13-S21